Business
Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
– Alignment reached with U.S. Food and Drug Administration on key elements of the approval pathway for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer – – Positive Preliminary Phase 1b/2 Data of Olvi-Vec in Advanced Small-Cell Lung Cancer – – Matt Pulisic joined the company as its new Chief Financial Officer – – Closing of $10.5 Million Underwritten Offering of Common Stock – – $30.9 million in cash, cash equivalents and short-term investments – WESTLAKE VILLAGE, Calif., March 28, 2025
About this update from Genelux Corporation
[{"type":"image","alt":"Genelux Corporation","displaySize":"","headline":null,"caption":"Genelux Corporation","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":75,"url":"https://media.zenfs.com/en/globenewswire.com/555a19f80dbf3a9d98dbd557739b10ea"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/PqbnzpB7NuWaPPuiKZD5BA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/555a19f80dbf3a9d98dbd557739b10ea","width":300,"height":75}},"lazy":false},{"type":"text","content":"– Alignment reached with U.S. Food and Drug Administration on key elements of the approval pathway for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer –","length":166,"tagName":"p"},{"type":"text","content":"– Positive Preliminary Phase 1b/2 Data of Olvi-Vec in Advanced Small-Cell Lung Cancer –","length":92,"tagName":"p"},{"type":"text","content":"– Matt Pulisic joined the company as its new Chief Financial Officer –","length":80,"tagName":"p"},{"type":"text","content":"– Closing of $10.5 Million Underwritten Offering of Common Stock –","length":76,"tagName":"p"},{"type":"text","content":"– $30.9 million in cash, cash equivalents and short-term investments –","length":80,"tagName":"p"},{"type":"text","content":"WESTLAKE VILLAGE, Calif., March 28, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, reported fourth quarter and full year 2024 financial results and business updates.","length":226,"tagName":"p"},{"type":"text","content":""Our progress in the fourth quarter of 2024 and into 2025 marks a pivotal period for patients, our company, and our investors,” said Thomas Zindrick, President, CEO and Chairman of Genelux. “We are pleased with the continued progress and promise of our clinical development program. The strengthening of our management team, with the addition of Matt, and of our balance sheet, with our recent financing, further positions the Company to execute on our mission to transform the lives of patients who need it most."","length":524,"tagName":"p"},{"type":"text","content":"Pipeline Highlights","length":19,"tagName":"p"},{"type":"text","content":"OnPrime/GOG-3076 Phase 3 Registrational Trial Update","length":52,"tagName":"p"},{"type":"text","content":"The Company continues to enro...